SavedAdd your journal

Journals / Kadın Doğum Dergisi / 2004 / Cilt: 3 - Sayı: 1

Effects of different hormone replacement therapies on serum androgen levels in postmenopausal women

Postmenopozal dönemde verilen farklı hormon replasman tedavilerinin serum androjen düzeylerine etkileri

Cemal ATALAY
Ferit SARAÇOĞLU
Özen OKAY
Pages
387–392
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Since androgens were decreased after E2+NETA therapy additional studies are needed for androgen replacement.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective:To investigate the level of androgens after different Hormone Replacement therapies in postmenopausal women.
📊
Key Findings & Data:Material and Methods: In a prospective study tibolone 2,5 mg/day and 170 estradiol 1 mg+noretiltestosteron (NETA) was administered randomly in 68 postmenopausal women.
💡
Conclusion & Impact:Since androgens were decreased after E2+NETA therapy additional studies are needed for androgen replacement.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective:To investigate the level of androgens after different Hormone Replacement therapies in postmenopausal women. Material and Methods: In a prospective study tibolone 2,5 mg/day and 170 estradiol 1 mg+noretiltestosteron (NETA) was administered randomly in 68 postmenopausal women. E2, FSH, total and Free testosteron DHEA-S04 and 17-OH progesteron were measured before and after 8 months of therapies in either group. Results: Althowgh in E2+NETA group DHEA-SO4, Free testosteron and 170H-progesteron was found to be decreased after therapy in tibolon group the level of these hormones were significantly increased.FSH level were decreased in both of the groups however in E2+NETA group it was significantly lower than that of the tibolon group. E2 level were increased in both of the groups but the difference between the groups was not significant. Conclusion: Effect of diferent hormone replacement therapies on serum androgen levels in postmenopausal women were found to be different. Since androgens were decreased after E2+NETA therapy additional studies are needed for androgen replacement.

Özet

Amaç: Bu çalışmada, postmenopozal dönemdeki hastalara verilen farklı HRT rejimlerinin, serum androjen düzeyleri üzerinde yaptığı değişiklikler incelendi. Materyal ve Metod: Çalışma prospektif randomize olarak en az bir yıldır doğal yoldan menopoza girmiş olan, 43-57 yaş arsındaki toplam 68 hasta üzerinde yapıldı. İlk gruba tibolon 2.5 mg/gün;ikinci gruba 17-beta östradiol 1 mg + noretiltestosteron asetat (NETA) 0.5 mg/gün kontinü tedavi olarak verildi.Alınan açlık serum örneklerinden ECLIA yöntemi ile östradiol, FSH ve total testosteron; RIA yöntemi ile de serbest testosteron, DHEA-S,17-OH progesteron çalışıldı. Tedavi öncesi ve tedaviden 8 ay sonraki serum değerleri her iki grup arasında karşılaştırıldı. Bulgular: E2 + NETA verilen grupta serbest testosteron, DHEA-S ve 17-OH progesteron düzeylerinde düşüş saptanırken; tibolon verilen grupta artış saptanmış ve her iki grup arasında istatistiksel olarak anlamlı fark bulunmuştur (p değerleri sırasıyla 0.001, 0.001, 0.003). Östradiol düzeyi E2 + NETA verilen grupta daha fazla olmak üzere her iki grupta artmış, FSH düzeyleri yine E2 +NETA verilen grupta daha fazla olmak üzere her iki grupta da azalmış olarak saptanmıştır.Östradiol düzeyinde artma ve FSH düzeyindeki azalma açısından her iki grup arasında istatistiksel olarak anlamlı fark saptanmıştır (p değerleri sırasıyla 0.029, 0.001). Total testosteron düzeyleri her iki grupta azalmış ancak her iki grup arasında istatistiksel olarak anlamlı fark saptanmamıştır (p

🔖

Cite This Article

ATALAY, C., SARAÇOĞLU, F., OKAY, Ö. (2022). Effects of different hormone replacement therapies on serum androgen levels in postmenopausal women. Kadın Doğum Dergisi, Cilt: 3 - Sayı: 1, 387–392. https://ajindex.com/articles/569104

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Speroff L.: Mcnapausc and postmenapausal hormone thcrapy.In.Glass R.H., Kase N.G., Speroff L.(eds). Clinical Gynecologic Endocrinology and Infertility. 5th. Ed. Wiiliams X Wilkins. 2001
  2. Ch: 18:583-649 2-Dowsett M, Cantvvcll B, Lal A ct al. Suprcssion of postmenopausal ovarian steroidogenesis with the luteinizing hormone releasing hormone agonist goscrelin. J Clin Endocrinol Metab 1988
  3. 677 3-Burger HG, Dudley EC, HopperJL et al.The endocrinology of the menopausal transition: A cross-sectional study of a population-based sample. J Clin Metab 1995
  4. 3545, 4-Casson PR. Effect of postmenopausal estrogen replacement on circulating androgens. Obstetrics and Gynecology 1997
  5. 998 5-Frye RF, Krobolh PD, Stone RA, Folan M ct al. Sex differences in the pharmacokineticks of DHEA after single and multip! dose administration in healty olderadults. J Clin Pharmacol 2000
  6. Abraham ct al. Effect of exogenous estrogen on serum pregnenolone, Cortisol and androgens in postmenopausal women. Obstet Gynccol 1975
  7. Obel EB, Jensen M., Svenstrup B, Bennett P, Micic S, Nielsen H. A two-year double blind controlled study of the clinical effect of combined and sequential postmenopausal replacement thcraphy and steroid metabolism during treatment. Maturitas 1993
  8. 21 8-Liu CH, Laughlin GA, Fischer LJG, Yen SSC. Marked attenuation of ultradian and circadicn rhythms of dehydroepiandrosteronc in postmenopausal women: Evidence fora reduced 17,20-desmolase enzymatic activity. J Clin Endoc Metab 1990
  9. Andreyko JL, Monroe SE, Marshall LA et al. Concordant suprcssion of serum immunoreactive LH, FSH and testosterone in postmenopausal women by a potent GnRH antagonist J Clin Endocrinol Metab 1992
  10. 399 10-Slater CC, Zhang C.Hodis HN, Mack WJ. Comparison of estrogen and androgen levels after oral estrogen replacement therapy. J Reprod Med 2001
  11. 1056 11-Gower B, Nyman L. Associations among oral estrogen use, free testosterone concentration, and lean body mass among postmenopausal women. J Clin Endoc Metab. 2000
  12. 4480 12-Ylösta İD P, Kauppila A, Kivincn S. Endocrine and metabolic effects of low-dose estrogen-progestin treatment in climactcric Women. Obstetrics and Gynecology 1983
  13. 686 13-Stomati M, Hartmann B, Spinetti A. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels İn postmenopausal women. J.Endocrinol Invest 1996